Sound fa­mil­iar? Chi­na/US biotech hy­brid lands rights to can­cer drugs, cash and a team of de­vel­op­ment vets to launch On­colo­gie

Look­ing for a new and sud­den­ly pop­u­lar busi­ness mod­el?

An­oth­er transpa­cif­ic biotech has launched with the back­ing of an emerg­ing group of ven­ture in­vestors in Chi­na as well as a plan to build a pipeline of can­cer drugs that can be swift­ly de­vel­oped for the boom­ing Asian mar­ket. Not sur­pris­ing­ly, they’re get­ting start­ed by fo­cus­ing on drug com­bi­na­tions us­ing red-hot check­point ther­a­pies to amp up re­spons­es for tar­get­ed ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER